NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $3.43 -0.08 (-2.28%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$3.42 -0.01 (-0.15%) As of 04/4/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.26▼$3.5650-Day Range$3.00▼$3.9152-Week Range$1.58▼$7.27Volume914,194 shsAverage Volume1.35 million shsMarket Capitalization$303.90 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingModerate Buy Company OverviewAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreAMLX MarketRank™: Amylyx Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 430th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.88% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 2.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth.Read more about Amylyx Pharmaceuticals' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.88% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 2.74%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.30 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Amylyx Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold 583.16% more of their company's stock than they have bought. Specifically, they have bought $37,000.00 in company stock and sold $252,769.00 in company stock.Percentage Held by Insiders11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Stock News HeadlinesJames M. Frates Sells 10,896 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) StockApril 3 at 5:53 AM | insidertrades.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Acquires $37,000.00 in StockMarch 25, 2025 | insidertrades.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 5, 2025 | American Alternative (Ad)Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Target Price at $7.33April 3 at 1:37 AM | americanbankingnews.comAmylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2 at 10:35 AM | finance.yahoo.comIs Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comAmylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...March 5, 2025 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $3.78 on January 1st, 2025. Since then, AMLX stock has decreased by 9.3% and is now trading at $3.43. View the best growth stocks for 2025 here. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings data on Tuesday, March, 4th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.06. The business had revenue of ($0.67) million for the quarter. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amylyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings3/04/2025Today4/05/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMLX CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$7.33 High Stock Price Target$12.00 Low Stock Price Target$3.00 Potential Upside/Downside+113.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net MarginsN/A Pretax Margin-131.04% Return on Equity-36.97% Return on Assets-29.61% Debt Debt-to-Equity RatioN/A Current Ratio4.55 Quick Ratio4.55 Sales & Book Value Annual Sales$87.37 million Price / Sales3.48 Cash Flow$0.62 per share Price / Cash Flow5.51 Book Value$6.42 per share Price / Book0.53Miscellaneous Outstanding Shares88,602,000Free Float60,528,000Market Cap$303.90 million OptionableOptionable Beta-0.51 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:AMLX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.